Accreditation/Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 21.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 21.5 Contact Hours.
This activity is supported by educational grants from AbbVie, Ariad Pharmaceuticals, Inc., Celgene Corporation, Foundation Medicine, Inc., Gilead Sciences, Inc., Incyte, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pharmacyclics, Seattle Genetics, Inc., and Takeda Oncology.
21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma
February 23-25, 2017
Trump International Miami
18001 Collins Avenue
Sunny Isles, FL 33160
Now in its 21st year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma is designed to facilitate clinician application of the wealth of emerging data in treating hematologic malignancies, choosing appropriate treatment based upon patient and tumor characteristics, and applying novel management strategies to their practices to improve the care of patients.
New for this year! We have shifted the meeting day pattern for this 3-day meeting to Thursday through mid-afternoon Saturday. This year’s program will focus on key clinical applications in leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, benign hematologic disorders, and mitigation and management of adverse events. Patient cases will be presented and discussed with the audience in a manner designed to engage their participation and in the context of methods to practically apply pivotal trial data to everyday practice. Additionally, the well-known and highly interactive Medical Crossfire® discussion panels will allow for exploration of some of the most challenging topics for which there may be many potential approaches to care.
This highly practical and interactive forum will provide a unique opportunity for oncologists and other healthcare professionals to learn from and interact with leading expert national faculty in order to increase their clinical knowledge, apply new data to practice, and ultimately improve patient outcomes.
This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.
At the conclusion of this symposium, you should be better prepared to:
- Describe current and evolving genomic and molecular biomarkers that can be used to stratify risk and inform clinical decision-making in the management of hematologic malignancies
- Assess landmark clinical trial results in the context of how they impact evolving clinical practice paradigms and can be applied to personalize care and optimize outcomes
- Delineate effective strategies to proactively mitigate and manage predictable side effects related to the management of hematologic malignancies so that treatment outcomes can be maximized
- Evaluate recent clinical trial findings concerning novel compounds or strategies to manage hematologic malignancies
- Consider the therapeutic implications of emerging data on evolving treatment paradigms for patients with hematologic tumors
Andre Goy, MD, MS
Chairman and Director, Chief of Lymphoma
Director, Clinical and Translational Cancer Research
John Theurer Cancer Center
Hackensack Meridian Health
Professor of Medicine, Georgetown University
Sagar Lonial, MD, FACP
Professor, Emory School of Medicine
Chair, Department of Hematology & Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
You must be logged in to PER to register for this meeting
Or Register for PER now
In case of onsite emergency:
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventative measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, or I have been in close contact with anyone that has been diagnosed with COVID-19, then I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.